US patent for simple, low-cost nucleic acid test:
This article was originally published in Clinica
Molecular Innovations has received a US patent covering its portable, easy-to-use, self-contained system for isolating, amplifying and sequencing DNA or RNA. The system, which can be used to detect specific nucleic acid sequences corresponding to genetically-linked diseases, may provide an economical and simple point-of-care tool for detecting disease predisposition and for monitoring patient response to treatment. The device could overcome the cost and ease-of-use hurdles of transferring nucleic acid-based testing to routine clinical or field testing faced by other methods currently used for genetic testing, said the Denver, Colorado-based company.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.